Belgium ’s Ablynx submits marketing authorisation application for caplacizumab approval

Belgium-based Ablynx has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for approval of caplacizumab anti-von Willebrand factor (vWF) Nanobody to treat acquired thrombotic thrombocytopenic purpura (aTTP).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news

Related Links:

Authors: Gómez-De León A, Villela-Martínez LM, Yáñez-Reyes JM, Gómez-Almaguer D Abstract Introduction: Thrombotic thrombocytopenic purpura (TTP) is an infrequent but fatal disease. Plasma exchange and corticosteroids continue to be the mainstay of treatment; however, repurposed drugs and novel agents are emerging as efficient treatment options.Areas covered: In this review, new therapeutic developments in immune-mediated TTP including rituximab, bortezomib, N-acetylcysteine, caplacizumab, and recombinant ADAMTS13, among others, are summarized.Expert opinion: Evidence on the...
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research
Hemophilia and von Willebrand disease (VWD) are the most common congenital coagulation factor deficiencies. Patients with these disorders who experience bleeding complications are often initially managed in the emergency department (ED).
Source: The Journal of Emergency Medicine - Category: Emergency Medicine Authors: Tags: Clinical Reviews Source Type: research
Acquired von Willebrand syndrome is implicated in the pathology of gastrointestinal bleeding (GIB) after implantation of continuous-flow left ventricular assist systems (CF-LVAS). Adults with blood type (BT) O have lower circulating levels of von Willebrand factor. In this analysis, we sought to explore the association between BT O and GIB following CF-LVAS implantation.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: (38) Source Type: research
In this study, a typical axial flow LVAD was redesigned using aerodynamics-based strategies to improve its hemodynamics and hence clinical outcomes for recipients.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: (1044) Source Type: research
Abstract A disintegrin and metalloproteinase with thrombospondin motifs 13 (ADAMTS13) was mainly generated and secreted from endothelial cells (ECs). Our previous study showed that tryptophan (Trp) residues at 387 and 390 in ADAMTS13 are required for its secretion and enzymatic activity. However, the effects on its host cell as well as the potential mechanism have not been clear. The aim of the study was to examine the effects of Trp residues 387 and 390 of ADAMTS13 on the biological processes of ECs. Herein, Trp was substituted with alanine in ADAMTS13 to generate ADAMTS13 mutants at 387 (W387A), 390 (W390A), and...
Source: Clinical and Experimental Pharmacology and Physiology - Category: Drugs & Pharmacology Authors: Tags: Clin Exp Pharmacol Physiol Source Type: research
Condition:   Liver Transplant; Complications Intervention:   Procedure: LT Sponsor:   Asan Medical Center Active, not recruiting
Source: - Category: Research Source Type: clinical trials
AbstractThrombotic thrombocytopenic purpura (TTP) is a life-threatening thrombotic microangiopathy caused by severely reduced activity of the von-Willebrand factor-cleaving protease ADAMTS13, mainly caused by anti-ADAMTS-13 antibodies. Although several test systems for ADAMTS13 measurement exist, long turn-around times hamper the usability in daily practice. We performed a method comparison study for two commercially available ADAMTS13 assays and evaluated the agreement between the fully-automated rapid turn-over HemosIL AcuStar ADAMTS13 Activity assay and the manually performed TECHNOZYM ADAMTS-13 Activity assay. Twenty-f...
Source: Journal of Thrombosis and Thrombolysis - Category: Hematology Source Type: research
Condition:   ARDS, Human Intervention:   Diagnostic Test: VWF measurement Sponsor:   Ain Shams University Not yet recruiting
Source: - Category: Research Source Type: clinical trials
More News: Belgium Health | European Medicines Agency (EMA) | Marketing | Nanotechnology | Pharmaceuticals | von Willebrand Disease